coteauBeta Get App

AZN

AstraZeneca PLC
$168.45
-0.22% Oct 21 close
Healthcare CompareTechnicals
-6%+2%+10%+18%+26%Oct 2025Oct 2026Apr 2026
AZNSPY
1W
+4.0%
1M
+0.2%
3M
-0.8%
6M
-13.5%
YTD
-7.4%
1Y
+2.3%

Live chart

Loading live chart…

What they do

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq.

Healthcare · Drug Manufacturers - General

For information only · Important disclosures

Grades vs sector

No sector grades for AZN yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Our models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
Momentum Top 15
Outside this model's universe or screens
Momentum Blend
Not in the current book
New Highs Growth
Outside this model's universe or screens
Coteau Long Book
Not in the current book

News

More news
AstraZeneca's Tezspire Shows Sustained Benefits In Phase 3 Esophagitis Trial
Nasdaq · Oct 20
Should You Be Worried About Tempus AI Stock?
Trefis · Oct 20
Haleon And 2 British AI Healthcare Stocks To Watch
Simply Wall St. · Oct 18
European Indexes Largely Rise, Though AI Stocks Fall
The Wall Street Journal · Oct 13

Key stats

Market value$261.3B
P/E (last 12 months)25.2
P/E (next 12 months, estimated)14.9
52-week range$153.41 – $212.71
Revenue growth (latest quarter vs a year ago)+6.4%
Dividend yield1.90%
Analyst consensusBuy (12)
Average analyst price target$206.82 (+23%)
Valuation and fundamentals

Valuation & fundamentals

No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).

Earnings

Next report: 2026-10-30 · after close · EPS est 2.63
24-0724-1125-0225-0425-0725-1126-0426-070.001.32
EstimateActual (beat)Actual (miss)
ReportEPS estActualSurprise
2026-07-271.251.32+4.8%
2026-04-291.271.29+1.4%
2025-11-061.131.19+4.9%
2025-07-290.880.79-10.7%
2025-04-291.121.25+11.6%
2025-02-061.041.05+0.8%
2024-11-121.031.04+1.1%
2024-07-250.990.99-0.4%

Quarterly revenue

QuarterRevenueYoY
2026-06-30$15.4B+6.4%
2026-03-31$15.3B–
2025-12-31$15.5B–
2025-09-30$15.2B–
2025-06-30$14.5B–
Rating changes
Initiated
2026-08-24 · CICC started covering AZN at Outperform
Upgrade
2025-02-13 · UBS upgraded AZN from Neutral to Buy
Upgrade
2024-11-20 · UBS upgraded AZN from Sell to Neutral
Upgrade
2024-09-11 · Erste Group upgraded AZN from Hold to Buy
Reiterated
2024-08-12 · TD Cowen reiterated Buy on AZN
Reiterated
2024-05-30 · Argus Research reiterated Buy on AZN

Third-party analyst actions, not Coteau's views. All rating changes

Recent dividends

2026-02-19: $2.153 · 2025-08-08: $1.030 · 2025-02-21: $2.100 · 2024-08-09: $1.000 · 2024-02-22: $1.970 · 2023-08-10: $0.930 · 2023-02-23: $1.970 · 2022-08-11: $0.930
Insider trades
Sharma Mani
See Remarks · 2026-08-08
Buy
$3.2K
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-21 18:06:34 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app

Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.

Beta 0.9 · Oct 21, 2026